SUMMARY
# Neural Stem Cell Therapy for Alzheimer's Disease
## Background and Rationale
Neural stem cell therapy for Alzheimer's disease represents a paradigm-shifting approach to treating one of the most devastating neurodegenerative conditions of our time. This comprehensive Phase I clinical trial addresses a fundamental challenge in Alzheimer's pathophysiology: the progressive loss of neuronal populations coupled with the dramatic decline in endogenous neurogenesis that occurs with aging and disease p
METHODOLOGY NOTES
**Phase 1: Pre-Screening and Baseline Assessment (Weeks -8 to 0)**
• Screen 200 patients aged 55-85 with mild-to-moderate AD (MMSE 16-26, CDR 0.5-2.0)
• Obtain comprehensive medical history, neurological examination, and safety laboratory panel
• Perform baseline cognitive assessment using ADAS-Cog13, MMSE, CDR-SB, and ADCS-ADL
• Conduct structural MRI with hippocampal volumetry and DTI sequences
• Collect CSF for Aβ42, total tau, p-tau181 biomarkers via lumbar puncture
• Perform 18F-florbetapir PET imaging for amyloid burden quantification
• Randomize 120 eligible participants 1:1 to treatment vs. sham control groups
**Phase 2: NSC Preparation and Quality Control (Week -2)**
• Prepare allogeneic human hippocampal NSCs (CTX0E03) at 20×10^6 cells per dose
• Conduct sterility testing, mycoplasma screening, and cell viability assessment (>85%)
• Verify NSC phenotype markers (Nestin+, SOX2+, GFAP-) via flow cytometry
• Perform karyotype analysis and confirm absence of tumorigenic potentia